- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01983241
Werkzaamheid en veiligheid van alfa1-proteïnaseremmer (menselijk), gemodificeerd proces (alfa-1 MP) bij proefpersonen met longemfyseem als gevolg van alfa1-antitrypsinedeficiëntie (AATD) (SPARTA)
Een gerandomiseerde, dubbelblinde, placebogecontroleerde studie om de werkzaamheid en veiligheid te beoordelen van twee dosisregimes (60 mg/kg en 120 mg/kg) van wekelijkse intraveneuze alfa1-proteïnaseremmer (menselijk) bij proefpersonen met longemfyseem als gevolg van alfa1-antitrypsinedeficiëntie
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Buenos Aires
-
Vicente López, Buenos Aires, Argentinië, B1602DOH
- Grifols Investigative Site
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentinië, 5000
- Grifols Investigative Site
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australië, 2010
- Grifols Investigative Site
-
-
Queensland
-
Chermside, Queensland, Australië, 4032
- Grifols Investigative Site
-
-
South Australia
-
Adelaide, South Australia, Australië, 5000
- Grifols Investigative Site
-
-
Victoria
-
Fitzroy, Victoria, Australië, 3065
- Grifols Investigative Site
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Grifols Investigative Site
-
-
-
-
São Paulo
-
Santo André, São Paulo, Brazilië, 09060-650
- Grifols Investigative Site
-
São Paulo, São Paulo, Brazilië, 04023-061
- Grifols Investigative Site
-
São Paulo, São Paulo, Brazilië, 05403-000
- Grifols Investigative Site
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Grifols Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H3A8
- Grifols Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T3A11
- Grifols Investigative Site
-
-
-
-
-
Arhus C, Denemarken, 8000
- Grifols Investigative Site
-
Hellerup, Denemarken, 2900
- Grifols Investigative Site
-
-
-
-
-
Homburg Saar, Duitsland, 66421
- Grifols Investigative Site
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Duitsland, 69126
- Grifols Investigative Site
-
-
Hesse
-
Marburg, Hesse, Duitsland, 35043
- Grifols Investigative Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Duitsland, 45239
- Grifols Investigative Site
-
-
-
-
-
Tallinn, Estland, 13419
- Grifols Investigative Site
-
Tartu, Estland, 51014
- Grifols Investigative Site
-
-
-
-
-
Turku, Finland, 20520
- Grifols Investigative Site
-
-
-
-
Gironde
-
Pessac, Gironde, Frankrijk, 33604
- Grifols Investigative Site
-
-
Rhone
-
Bron, Rhone, Frankrijk, 69500
- Grifols Investigative Site
-
-
-
-
-
Chisinau, Moldavië, 2025
- Grifols Investigative Site
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1051
- Grifols Investigative Site
-
Christchurch, Nieuw-Zeeland, 8013
- Grifols Investigative Site
-
Hamilton, Nieuw-Zeeland, 3240
- Grifols Investigative Site
-
-
-
-
-
Krakow, Polen, 31-066
- Grifols Investigative Site
-
Warsaw, Polen, 01-138
- Grifols Investigative Site
-
-
-
-
-
Oradea, Roemenië, 410176
- Grifols Investigative Site
-
Timișoara, Roemenië, 300312
- Grifols Investigative Site
-
-
-
-
-
Barnaul, Rusland, 656038
- Grifols Investigative Site
-
Moscow, Rusland, 105077
- Grifols Investigative Site
-
Yaroslavl, Rusland, 150003
- Grifols Investigative Site
-
-
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanje, 33011
- Grifols Investigative Site
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spanje, 48903
- Grifols Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85013
- Grifols Investigative Site
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Grifols Investigative Site
-
Leesburg, Florida, Verenigde Staten, 34748
- Grifols Investigative Site
-
Miami, Florida, Verenigde Staten, 33136
- Grifols Investigative Site
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Grifols Investigative Site
-
-
North Carolina
-
Wilmington, North Carolina, Verenigde Staten, 28401
- Grifols Investigative Site
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Grifols Investigative Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Grifols Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Grifols Investigative Site
-
-
Texas
-
Tyler, Texas, Verenigde Staten, 75708
- Grifols Investigative Site
-
-
-
-
-
Gothenburg, Zweden, 41345
- Grifols Investigative Site
-
Linköping, Zweden, 587 58
- Grifols Investigative Site
-
Malmö, Zweden, 20502
- Grifols Investigative Site
-
Stockholm, Zweden, 11361
- Grifols Investigative Site
-
Uppsala, Zweden, 752 37
- Grifols Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Have a documented total alpha1-PI serum level < 11 µM.
- Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles.
- At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and < 80% of predicted and FEV1/forced vital capacity (FVC) < 70% (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II or III).
- Have a carbon monoxide diffusing capacity (DLCO) ≤ 60% of predicted (corrected for HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the past 2 years per the Investigator's judgment.
- Have clinical evidence of pulmonary emphysema per the Investigator's judgment.
Exclusion Criteria:
- Has received alpha1-PI augmentation therapy for more than 1 month within the six months prior to the Screening Visit.
- Has received alpha1-PI augmentation therapy within one month of the Screening Visit.
- Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g., claustrophobic) undergo a CT scan.
- History of lung or liver transplant.
- Any lung surgery during the past 2 years (excluding lung biopsy).
- On the waiting list for lung surgery, including lung transplant.
- Smoking during the past 12 months or a positive urine cotinine test at screening that is due to smoking. Maybe on Nicotine replacement, including vapor cigarettes.
- History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
- Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids are not considered systemic steroids) or during the Screening Phase.
- Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Known selective or severe Immunoglobulin A (IgA) deficiency.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Alpha-1 MP 60 mg/kg
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks |
Andere namen:
|
|
Experimenteel: Alpha-1 MP 120 mg/kg
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks |
Andere namen:
|
|
Placebo-vergelijker: Placebo
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks |
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Whole lung PD15 (15th percentile point)
Tijdsspanne: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
Whole lung PD15 measured by CT scan |
Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse Events (AEs)
Tijdsspanne: Week -3 through Week 160
|
Monitoring of AEs |
Week -3 through Week 160
|
|
Serious Adverse Events (SAEs)
Tijdsspanne: Week -3 through Week 160
|
Monitoring of SAEs |
Week -3 through Week 160
|
|
Discontinuations from the study due to AEs
Tijdsspanne: Week -3 through Week 160
|
Monitoring of discontinuations due to AEs |
Week -3 through Week 160
|
|
Severe COPD Exacerbations
Tijdsspanne: Week -3 through Week 160
|
Severe COPD exacerbations as defined by American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (i.e., COPD exacerbations requiring hospitalization) |
Week -3 through Week 160
|
|
Change from Baseline in PD15 of the basal lung region
Tijdsspanne: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
PD15 of the basal lung region measure by CT scan |
Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
|
Change from baseline in carbon monoxide diffusing capacity (DLco)
Tijdsspanne: Weeks 26, 52, 78, 104, 130 and 156
|
DLco performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Changes from baseline in forced expiratory volume in 1 second (FEV1)
Tijdsspanne: Weeks 26, 52, 78, 104, 130 and 156
|
FEV1 performed according to ATS/ERS guidelines |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Change from baseline in Saint George's Respiratory Questionnaire: Minimum value = 0, maximum value = 100, higher scores indicate worse condition
Tijdsspanne: Weeks 26, 52, 78, 104, 130 and 156
|
Health-related quality of life assessment tool |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Change from baseline in the EuroQoL (Quality of Life)- 5 Dimension- 5 Level (EQ-5D-5L): Minimum value (for each one of the 5 levels) = 1, maximum value (for each one of the 5 levels) = 5, higher scores indicate worse condition
Tijdsspanne: Weeks 26, 52, 78, 104, 130 and 156
|
Heath-related quality of life assessment tool |
Weeks 26, 52, 78, 104, 130 and 156
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Genetische ziekten, aangeboren
- Ziekten van de luchtwegen
- Ziekten van het spijsverteringsstelsel
- Longziekten
- Longziekten, obstructief
- Lever Ziekten
- Subcutaan emfyseem
- Emfyseem
- Longziekte, chronisch obstructief
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Longemfyseem
- Alpha 1-antitrypsinetekort
- Therapeutica
- Routes voor het toedienen van geneesmiddelen
- Drugstherapie
- Anorganische chemicaliën
- Chloorverbindingen
- Natriumverbindingen
- Chloriden
- Zoutzuur
- Injecties
- Natriumchloride
- Mp alpha1-receptor
Andere studie-ID-nummers
- GTi1201
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .